FMP
Oct 3, 2024 4:52 PM - Davit Kirakosyan
Image credit: FMP
TD Cowen analysts reaffirmed their Buy rating and maintained a $130 price target on Abbott Labs (NYSE:ABT) stock. The analysts expressed confidence that Abbott's upcoming third-quarter results will likely meet or exceed Wall Street expectations, positioning the company to achieve its full-year guidance.
The analysts pointed to several new product launches, including the recent introduction of Abbott's Lingo CGM sensor in the U.S., as key growth drivers. These developments, combined with the company's core business strength, bolster optimism for Abbott’s outlook, despite potential risks from the ongoing NEC litigation.
May 14, 2024 11:41 AM - Sanzhi Kobzhan
A stock's target price, also known as its fair value, is an indication of what a share can cost based on the company’s forecasted financial statements. It is important to know a stock's fair value to find undervalued stocks with great growth potential. Let's consider how investment analysts calculat...
May 24, 2024 9:30 AM - Rajnish Katharotiya
Earnings call transcripts are invaluable resources for investors, analysts, and financial enthusiasts. They provide insights into a company's performance, strategy, and future outlook, making them essential for making informed investment decisions. With Financial Modeling Prep, Earnings Call Transcr...
May 27, 2024 3:30 PM - Rajnish Katharotiya
In the ever-evolving world of technology, certain sectors have consistently demonstrated exceptional growth and innovation. The graphics processing units (GPUs) industry is one such sector, offering investors a golden opportunity for potentially high returns. In this blog, we'll delve into why inves...